About Zafgen (NASDAQ:ZFGN)
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003
Debt
Debt-to-Equity Ratio0.31
Current Ratio12.27
Quick Ratio12.27
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.85 per share
Price / Book2.47
Profitability
EPS (Most Recent Fiscal Year)($1.90)
Net Income$-52,020,000.00
Net MarginsN/A
Return on Equity-66.22%
Return on Assets-54.53%
Miscellaneous
Employees35
Outstanding Shares27,560,000
Zafgen (NASDAQ:ZFGN) Frequently Asked Questions
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen Inc (NASDAQ:ZFGN) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.06. View Zafgen's Earnings History.
When is Zafgen's next earnings date?
What price target have analysts set for ZFGN?
2 analysts have issued twelve-month price targets for Zafgen's shares. Their predictions range from $20.00 to $20.00. On average, they anticipate Zafgen's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Zafgen.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include Urogen Pharma (URGN), Vectura Group (VEGPF), Geron (GERN), Homology Medicines (FIXX), Odonate Therapeutics (ODT), Arcus Biosciences (RCUS), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Dicerna Pharmaceuticals (DRNA), Evolus (EOLS), Viking Therapeutics (VKTX), CannTrust (CNTTF), Progenics Pharmaceuticals (PGNX), Kura Oncology (KURA) and Aduro BioTech (ADRO).
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Dr. Thomas E. Hughes, Pres, Chief Scientific Officer & Director (Age 58)
- Ms. Patricia L. Allen, Chief Financial Officer (Age 56)
- Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 48)
- Mr. Jeffrey S. Hatfield, CEO & Director (Age 60)
- Dr. James E. Vath Ph.D., Head of Discovery and Devel. (Age 57)
Has Zafgen been receiving favorable news coverage?
News stories about ZFGN stock have been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zafgen earned a news impact score of 0.20 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Zafgen's major shareholders?
Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Artal Group S.A. (4.35%), Dimensional Fund Advisors LP (3.14%), Nexthera Capital LP (1.46%), Citadel Advisors LLC (1.14%), Millennium Management LLC (0.66%) and Spark Investment Management LLC (0.38%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller, Patricia L Allen and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.
Which institutional investors are selling Zafgen stock?
Which institutional investors are buying Zafgen stock?
ZFGN stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Nexthera Capital LP, Artal Group S.A., Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., Tibra Equities Europe Ltd, Millennium Management LLC and Algert Global LLC. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim, Frances K Heller, Patricia L Allen and Thomas E Hughes. View Insider Buying and Selling for Zafgen.
How do I buy shares of Zafgen?
Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of ZFGN stock can currently be purchased for approximately $7.04.
How big of a company is Zafgen?
Zafgen has a market capitalization of $194.04 million. The biopharmaceutical company earns $-52,020,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 35 workers across the globe.
How can I contact Zafgen?
Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]
MarketBeat Community Rating for Zafgen (ZFGN)
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
